Üstün G.Altay B.Ekren F.Turna B.Semerci B.Çikili N.2019-10-272019-10-2720061300-58041300-5804https://hdl.handle.net/11454/21759Introduction: Prostate cancer is one of the most important malignancies of male population because of its high morbidity and mortality. Early detection is important to obtain better treatment outcome. Prostate specific antigen (PSA) is a key marker for early detection of prostate cancer. The aim of this retrospective study is to compare prostate specific antigen (PSA) and free/total PSA (f/t PSA) ratios in patients with benign prostatic hyperplasia (BPH) and prostate cancer. In addition, PSA alterations' correlation with Gleason score in prostate cancer patients and age-specific PSA levels in BPH patients were analysed. Materials and methods: A total of 662 patients, who underwent surgical treatment for BPH or patients diagnosed with primary prostate cancer at Urology Department of Ege University between January 2001 and December of 2003, were recruited in the current study. All data were achieved from patient data archives retrospectively. Patients were analysed in 2 groups: BPH (543 patients) and prostate cancer (119 patients) patients. We compared PSA, f/t PSA ratios and PSA density (PSA-D) between 2 groups. We also reviewed the correlation between PSA levels and Gleason score in prostate cancer patients and age-specific PSA levels in BPH patients. Statistical analysis was done with SPSS 10.0. Results: 321 of 543 BPH cases underwent transurethral resection of prostate (TURP) and 222 BPH cases underwent suprapubic transvesical prostatectomy (SPTVP). 9 patients were diagnosed as prostate cancer pathologically who were considered as clinically BPH preoperatively. Median ages of the patients with BPH and prostate cancer are 68.5 and 66.9 years old, respectively. Median PSA in prostate cancer group was 32.3 ng/ml (0.4-165.6. ng/ml) and median PSA in BPH group was 5.3 ng/ml (0.2-19.4 ng/ml). 51 out of 543 BPH patients have PSA values more than 10 ng/ml (rate %9.3). f/t PSA ratios were available in 66 patients with prostate cancer. Median and mean f/t PSA ratios in this group were 0.14 (0.01-0.72) and 0.12, respectively. In BPH group, median and mean f/t PSA ratios were 0.19 (0.01-0.70) and 0.19, respectively. Mean PSA levels of prostate cancer patients with Gleason score of below 7.7 and above 7 were 22.7, 35.9, 32, respectively. Mean PSA levels stratified according to decades in BPH patients were 1.9 in 40-49 years old group, 3.4 in 50-59 years old group, 4.2 in 60-69 years old group, 5.8 in 70 years old and older group. Median and mean PSA density in prostate cancer (58 patients) cases were 1.38 and 0.54, respectively whereas median and mean PSA density in BPH (420) cases were 0.08 and 0.06, respectively. Conclusion: There is significant difference between prostate cancer and BPH patients with regards to f/t PSA and PSA-D values. In addition, PSA levels correlate well with Gleason scores in prostate patients. Age-specific PSA values are valid in BPH patients.trinfo:eu-repo/semantics/closedAccessBPHProstate cancerPSAPSA derivatesArticle3213742N/A